Navigation Links
Alseres Pharmaceuticals, Inc. Announces $1 Million Financing
Date:1/13/2009

nd potentially dementia. The Company's lead molecular imaging product candidate is Altropane which is in Phase III clinical trials for the diagnosis of Parkinsonian Syndromes including Parkinson's Disease. The Company has research collaborations with Harvard Medical School and Children's Hospital Boston.

Forward-Looking Statements

The foregoing release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding Alseres' future expectations, beliefs, intentions, goals, strategies, plans or prospects regarding the future, including the Company's ability to obtain financing, the development and commercialization of Altropane and Cethrin, the prospects of the Company's CNS and regenerative therapeutics programs, the Company's strategies to develop and commercialize axon regeneration technologies and the breadth of the Company's technologies and intellectual property portfolio. Forward-looking statements can be identified by terminology such as "anticipate," "believe," "could," "could increase the likelihood," "estimate," "expect," "intend," "is planned," "may," "should," "will," "will enable," "would be expected," "look forward," "may provide," "would" or similar terms, variations of such terms or the negative of those terms. Such forward-looking statements involve known and unknown risks, uncertainties and other factors including those risks, uncertainties and factors referred to in the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2008 filed with the Securities and Exchange Commission under the section "Risk Factors," as well as other documents that may be filed by Alseres from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, the Company's actual results may differ materially from any future results, performance or achieveme
'/>"/>

SOURCE Alseres Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results
2. Alseres Pharmaceuticals, Inc. Raises $5 Million
3. Alseres Pharmaceuticals, Inc. Reports 2007 Financial Results and Provides Company Highlights
4. Alseres Pharmaceuticals to Host 2007 Financial Results Conference Call
5. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
6. Alseres Pharmaceuticals, Inc. to Present at Windhovers Therapeutic Area Partnerships Conference
7. Alseres Pharmaceuticals, Inc. to Present at Bio Investor Forum 2007 Annual Meeting
8. Johnson & Johnson Completes Acquisition of Omrix Biopharmaceuticals, Inc.
9. Chemical Engineering Conference Highlights Energy, Biomedicine, Pharmaceuticals, Sustainability and Centennial
10. Transdel Pharmaceuticals, Inc. Retains The Investor Relations Group
11. Transcept Pharmaceuticals, Inc. to Present at the Natixis Bleichroeder Second Annual Hidden Gems Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... , Jan. 22, 2015   GenoSpace , a precision medicine ... to enable the broad use of genomic, imaging and other ... appointment of Michelle Munson , CEO of Aspera, an ... Logo - http://photos.prnewswire.com/prnh/20150122/170713 "We ...
(Date:12/24/2014)... SILVER SPRING, Md. , Dec. 24, 2014  United ... that Medtronic, Inc. (NYSE: MDT ) has ... and Drug Administration (FDA) for the use of Medtronic,s ... a newly developed catheter) for use with United Therapeutics, ...
(Date:12/24/2014)... , Dec. 24, 2014   BioLife Solutions , Inc. ... marketer of proprietary clinical grade hypothermic storage and ... products for cells and tissues  ("BioLife" or the "Company"), ... of Stockholders on May 4, 2015 (the "Annual Meeting"). ...
(Date:12/24/2014)... 2014 Earlier this year in a June ... the Adult Stem Cell Technology Center, LLC ( ASCTC ) ... property of adult tissue stem cells. His title “Asymmetric ... for the Future,” embodied the essence of his message to ...
Breaking Biology Technology:GenoSpace Expands Board with Appointment of Michelle Munson 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4BioLife Solutions Sets Date for Annual Meeting of Stockholders 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4
... Approved in Atlanta ATLANTA, May 19 Meeting ... the Kansas Bioscience Authority has approved more than ... a $581 million initiative to help researchers and ... at the Bio International Convention will create bioscience ...
... availability of the world,s first clinical guidelines to allow U.S. doctors ... disease. , ... Broomfield, CO (PRWEB) May 19, 2009 ... today the availability of the world,s first clinical guidelines to allow ...
... illustrate potential cost effective approach for, ... Symbol: RVX,CALGARY and ATLANTA, May 19 /PRNewswire-FirstCall/ - ... pleased to announce today that it has made ... (R&D) program for inflammatory diseases. Two new patent ...
Cached Biology Technology:As Other States Pull Back, Kansas Accelerates Innovation Investments at Bio International Convention 2As Other States Pull Back, Kansas Accelerates Innovation Investments at Bio International Convention 3As Other States Pull Back, Kansas Accelerates Innovation Investments at Bio International Convention 4Physician's Organization Makes History by Publishing U.S.'s First Adult Stem Cell Guidelines (ASCTA Drives Safe Stem Cell Practices) 2Physician's Organization Makes History by Publishing U.S.'s First Adult Stem Cell Guidelines (ASCTA Drives Safe Stem Cell Practices) 3Physician's Organization Makes History by Publishing U.S.'s First Adult Stem Cell Guidelines (ASCTA Drives Safe Stem Cell Practices) 4Resverlogix's Success in Inflammation Program Results in 2 Patents Filed 2Resverlogix's Success in Inflammation Program Results in 2 Patents Filed 3
(Date:12/24/2014)... Dec. 23, 2014  Since its launch in December 2014, the ... the pain of trying to remember their usernames and passwords ... to their smartphones. To assist people who have struggled to ... that created 1U and focuses on redefining identity, announced today ...
(Date:12/22/2014)... 22, 2014 Research and Markets ( ... "The Global Watermarking and Fingerprinting Markets" ... http://photos.prnewswire.com/prnh/20130307/600769 This insight provides ... and fingerprinting markets. Watermarking aims to control and ...
(Date:12/19/2014)... Research and Markets ( http://www.researchandmarkets.com/research/8kmfcn/iphone_5s ) has ... Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report" ... http://photos.prnewswire.com/prnh/20130307/600769 Following the acquisition of ... feature with the iPhone 5S. It is currently the ...
Breaking Biology News(10 mins):1U Offers Best Solution to the Username / Password Dilemma: For FREE! 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 3The Global Watermarking and Fingerprinting Markets 2iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 2
... of cancer cells can be switched on using drugs, ... Center. The finding could lead to a new class ... different cancer types. , Popular new drugs such as ... genetic mutations that express themselves in large amounts, causing ...
... the battle against Alzheimer's disease, physician-scientists at NewYork-Presbyterian ... antibodies in human blood that may help to ... as other neurodegenerative diseases. , The newly ... proteins called "oligomers" that are toxic to brain ...
... the protein complex implicated in autism spectrum disorders, a ... California, San Diego (UCSD) Skaggs School of Pharmacy and ... this complex and contribute to the developmental abnormalities found ... cover article in the June issue of the journal ...
Cached Biology News:U-M researchers discover gene switched off in cancer can be turned on 2U-M researchers discover gene switched off in cancer can be turned on 3Newly discovered antibody may be body's natural defense against Alzheimer's 2Newly discovered antibody may be body's natural defense against Alzheimer's 3Researchers reveal structure of protein altered in autism 2
... anti-phospho-FAK (Ser843) ... acid region encompassing the human, mouse, ... Accession Number: NM_153831 ... Routinely evaluated by immunoblot. ...
Molecular Biology grade. Ideally suited for DNA and RNA separation and recovery. High gel strength. Gelling temp. 36C. Melting temp. 88C. EEO: 0.05-0.13 Resolution 0.2-40 kb; Rnase/Dnase: none detec...
Rabbit polyclonal to Quinolinic acid ( Abpromise for all tested applications). Antigen: Synthetic quinolinic acid conjugated to bovine serum albumin....
Phospho-YAP (Ser127) Antibody Ship: Hot Store: -20 C...
Biology Products: